Cortesi PA, Paolicelli D, Capobianco M, et al. The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis. Farmeconomia. Health Economics and Therapeutic Pathways. 2019;20(1). https://doi.org/10.7175/fe.v20i1.1435